Vinay Prasad, High-Risk Drugs and the FDA

Wall Street Journal

4 days ago

In 'Vinay Prasad Is a Bernie Sanders Acolyte in MAHA Drag,' Allysia Finley is off base in her criticism of Dr. Prasad (Life Science, July 28). He is an excellent clinical oncologist and highly skilled epidemiologist who understands the intricacies of scientific studies and data. It is a shame that criticism of him led to his resignation under pressure this week. He apparently couldn't manage the political jungle.
The issue of U.S. Food and Drug Administration drug approvals is more nuanced than Ms. Finley makes it out to be. Dr. Prasad was right to encourage the thoughtful and careful evaluation of higher-risk drugs at the FDA.